• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Genomics England launched, DNA mapping

Genomics England launched, DNA mapping

July 10, 2013
CenterWatch Staff

Genomics England, an organization owned by DH, has launched a personal DNA code project. The personal DNA code—known as a genome—of up to 100,000 patients or infections in patients will be sequenced over the next five years.

Genomics England will manage contracts for specialist U.K.-based companies, universities and hospitals to supply services on sequencing, data linkage and analysis. It will set standards for obtaining patient consent and also manage storage of personal data in accordance with existing NHS rules designed to protect patient information.

“The U.K. aims to become the first country to introduce this technology in its mainstream health system—leading the global race for better tests, better drugs and above all better, more personalized care to save lives,” said Jeremy Hunt, DH secretary.

Genomics England will be funded by DH in the medium term and any surplus will be invested back into improving health. It will be chaired by John Chisholm, former chair of the Medical Research Council.

“Genomics England will create a dataset of anonymized whole genome sequences matched with clinical data at a scale unique in the world,” said Chrisholm. “Participating patients will have the opportunity to benefit from clinical insights derived from the sequencing of their genome while at the same time contributing to knowledge which will be valuable to the whole patient community. It is from that knowledge that world leading therapeutic products and processes will become available to all patients.”

It is estimated that up to one in 17 people is born with or develop a rare disease during his lifetime. At least 80% of rare diseases have an identified genetic component, with 50% of new cases of rare diseases being identified in children. However, it can take considerable time and expense between a patient first presenting to a doctor and receiving an accurate diagnosis. The time taken to sequence a whole human genome has been reduced to one to two weeks and will become more affordable for routine use as the price continues to fall.

“By putting foundations in place through Genomics England, this technology will let us make ground-breaking discoveries about how diseases work, who could be susceptible to them, how we can treat them and what treatments might work,” said professor Sally Davies, chief medical officer.

Up to $128 million of funding pledged by the government will train a new generation of British genetic scientists to develop new drugs, treatments and scientific breakthroughs; train the wider healthcare community to use the technology; fund the initial DNA sequencing for cancer and rare and inherited diseases; and build the secure NHS data linkage to ensure that this new technology leads to better care for patients.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing